Key points are not available for this paper at this time.
We isolated aminoacyl-tRNA (60-70% yield) from human and rat tissues and measured, by GC/MS, its labeling in vivo by 15N- and 13Cleucine. Tracer dilution artifacts seemed unlikely since, after infusion of L-1-13C,15Nleucine into rats, (i) muscle leucyl-tRNA labeling exceeded tissue free leucine labeling, (ii) values were largely unaffected by storing over 5 min at 22 degrees C, and (iii) L-2,4,5-methyl-13Cleucine was not incorporated into leucyl-tRNA during homogenization. Leucyl-tRNA labeling in liver and muscle suggested charging from extra- and intracellular pools: e.g., after infusing L-1-13C,15Nleucine, rat muscle tissue free leucine 13C labeling (8.97 +/- 0.30 atom % excess) exceeded that by 15N (3.37 +/- 0.33 atom % excess), and both were significantly lower (P less than 0.02) than venous plasma (13C, 12.1 +/- 1.8; 15N, 5.54 +/- 0.6 atom % excess) indicating tracer dilution by transamination and by proteolysis; however, leucyl-tRNA labeling by either isotope (13C, 10.26 +/- 0.50; 15N, 4.72 +/- 0.72 atom % excess) was significantly above mixed tissue free leucine (P less than 0.05). Labeling of leucyl-tRNA in human erector spinae muscle (obtained after preoperative L-1-13Cleucine infusion) was, at 4.98 +/- 0.43 atom % excess, lower (27%) than venous plasma leucine (P less than 0.05) and intermediate between muscle free leucine (9% lower; P less than 0.01) and venous alpha-ketoisocaproate (11% higher; P less than 0.02). Human placental leucyl-tRNA labeling (after predelivery tracer infusion) was 37% lower (P less than 0.05) than maternal uterine vein labeling but not significantly different from placental free leucine or umbilical arterial leucine.
Watt et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: